Literature DB >> 19568813

Micromedullary thyroid cancer: how micro is truly micro?

Venu G Pillarisetty1, Steven C Katz, Ronald A Ghossein, R Michael Tuttle, Ashok R Shaha.   

Abstract

BACKGROUND: The aggressive nature of medullary thyroid cancer (MTC) is evidenced by its propensity to present early with lymph node (LN) metastases. The clinical significance of sporadic MTC < or =1 cm (micro-MTC) is not clearly defined.
METHODS: We performed a retrospective review of the clinical, laboratory, and pathologic data for all patients treated or followed at our institution for sporadic micro-MTC from 1987 through 2008.
RESULTS: A total of 18 patients met the criteria for inclusion in our study. All tumors were unifocal and C-cell hyperplasia distant from the tumors was uniformly absent. Fourteen (78%) patients underwent total thyroidectomy, and the remaining four (22%) patients with tumors < or =0.5 cm had lobectomy with isthmusectomy alone. Four (22%) patients were found to have LN metastases. However, none of the nine patients with tumors <0.5 cm had clinical evidence of LN metastases. Patients were followed for a median of 3.3 (mean, 4.5) years, and there were no deaths. Postoperative calcitonin levels were available for all patients, of whom 14 had normal levels (range, 0-3.9 pg/ml). The four patients with elevated postoperative calcitonin levels (range, 6.3-644 pg/ml) had tumors ranging from 0.7-0.9 cm in size.
CONCLUSIONS: Tumors <0.5 cm were associated with a complete absence of clinically detectable nodal disease or elevated postoperative calcitonin levels. The complete absence of multifocal or bilateral disease argues against the need for completion thyroidectomy for sporadic micro-MTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19568813     DOI: 10.1245/s10434-009-0595-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

3.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 4.  [Calcitonin determination for early diagnosis of medullary thyroid cancer].

Authors:  W Karges
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

Review 5.  Neuroendocrine Tumors of the Thyroid and Their Mimics.

Authors:  Virginia A Livolsi
Journal:  Endocr Pathol       Date:  2021-03-09       Impact factor: 3.943

6.  Concurrent Medullary, Papillary, and Follicular Thyroid Carcinomas and Simultaneous Cushing's Syndrome.

Authors:  Haggi Mazeh; Amir Orlev; Ido Mizrahi; David J Gross; Herbert R Freund
Journal:  Eur Thyroid J       Date:  2014-11-22

7.  Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis.

Authors:  Jin Hwa Kim; Jung-Soo Pyo; Won Jin Cho
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

8.  Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association.

Authors:  Rossella Elisei; Cristina Romei
Journal:  Thyroid Res       Date:  2013-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.